drugset

drugset / Trial / NCT00167947

Study Evaluating Sirolimus in Kidney Transplant Recipients.

NCT00167947 ↗

Phase 3 Completed 150 enrolled Wyeth is now a wholly owned subsidiary of Pfizer

RandomizedParallel-groupOpen-labelTreatment

Summary

Renal function at 12 months assessed by calculated creatinine clearance.

Timeline

Start: 2005-01
Primary completion: 2007-07
Completion: 2007-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cyclosporine	Peptide	—	—
Subject	Sirolimus	Small molecule	5 mg	—

Indications